{"log_id": 4497322937193264406, "direction": 0, "words_result_num": 31, "words_result": [{"probability": {"variance": 1.5e-05, "average": 0.998101, "min": 0.979015}, "location": {"width": 888, "top": 200, "height": 77, "left": 168}, "words": "肌酐,血尿素氮:在原发性高血压病人中,单独使用本品有不到0.1%的病人观察到血尿素氮"}, {"probability": {"variance": 3.5e-05, "average": 0.996408, "min": 0.983197}, "location": {"width": 194, "top": 279, "height": 39, "left": 172}, "words": "或血清肌酐轻微升高"}, {"probability": {"variance": 1.1e-05, "average": 0.998617, "min": 0.979995}, "location": {"width": 886, "top": 282, "height": 78, "left": 171}, "words": "血红蛋白和红细胞压积:在单独用本品治疗的病人中经常出现血红蛋白和红细胞压积的轻度下"}, {"probability": {"variance": 0.000104, "average": 0.994934, "min": 0.948987}, "location": {"width": 885, "top": 325, "height": 76, "left": 173}, "words": "降(分别平均下降约0.11%g和0.09%体积),但很少有临床重要性,没有病人因为贫血而中"}, {"probability": {"variance": 2.5e-05, "average": 0.997663, "min": 0.972522}, "location": {"width": 887, "top": 407, "height": 78, "left": 177}, "words": "肝功能检查:偶而有肝脏酶和/或血清胆红素升高。在单独用本品治疗的原发性高血压病人"}, {"probability": {"variance": 0, "average": 0.999365, "min": 0.998461}, "location": {"width": 67, "top": 412, "height": 29, "left": 177}, "words": "止服药"}, {"probability": {"variance": 0.009242, "average": 0.973073, "min": 0.48619}, "location": {"width": 549, "top": 467, "height": 58, "left": 180}, "words": "中,一个病人(K0.1%)由于这些实验室不良反应而停止服药"}, {"probability": {"variance": 1.1e-05, "average": 0.995118, "min": 0.991244}, "location": {"width": 68, "top": 577, "height": 26, "left": 185}, "words": "[禁忌]"}, {"probability": {"variance": 3e-06, "average": 0.998195, "min": 0.994622}, "location": {"width": 262, "top": 604, "height": 41, "left": 227}, "words": "对本品任何成份过敏者禁用"}, {"probability": {"variance": 0.000112, "average": 0.994391, "min": 0.973219}, "location": {"width": 101, "top": 697, "height": 30, "left": 192}, "words": "[注意事项"}, {"probability": {"variance": 0.000131, "average": 0.995608, "min": 0.952829}, "location": {"width": 350, "top": 723, "height": 47, "left": 189}, "words": "过敏反应:血管性水肿。见不良反应"}, {"probability": {"variance": 0.000171, "average": 0.994147, "min": 0.948044}, "location": {"width": 296, "top": 766, "height": 47, "left": 192}, "words": "低血压及电解质/体液平衡失调"}, {"probability": {"variance": 0.000303, "average": 0.995848, "min": 0.888844}, "location": {"width": 850, "top": 780, "height": 71, "left": 230}, "words": "血管容量不足的病人(例如应用大剂量利尿药治疗的病人),可发生症状性低血压。在使用"}, {"probability": {"variance": 2.2e-05, "average": 0.99777, "min": 0.973867}, "location": {"width": 668, "top": 832, "height": 62, "left": 195}, "words": "本品治疗前应该纠正这些情况,或使用较低的起始剂量。(见用法用量)"}, {"probability": {"variance": 4e-06, "average": 0.998799, "min": 0.990116}, "location": {"width": 851, "top": 904, "height": 71, "left": 235}, "words": "应当注意,在肾功能不全,伴或不伴有糖尿病的患者中常见电解质平衡失衡。在2型糖尿"}, {"probability": {"variance": 8e-06, "average": 0.998509, "min": 0.98821}, "location": {"width": 869, "top": 948, "height": 71, "left": 198}, "words": "病伴蛋白尿的患者中进行临床研究,氯沙坦钾治疗组高钾血症的发生率较安慰剂组高;然而"}, {"probability": {"variance": 2e-06, "average": 0.999104, "min": 0.994386}, "location": {"width": 618, "top": 997, "height": 63, "left": 202}, "words": "几乎没有患者因高钾血症中断治疗(见不良反应和实验室检查结果"}, {"probability": {"variance": 0, "average": 0.999758, "min": 0.999615}, "location": {"width": 111, "top": 1110, "height": 28, "left": 207}, "words": "肝功能损害"}, {"probability": {"variance": 2e-06, "average": 0.999036, "min": 0.994834}, "location": {"width": 839, "top": 1111, "height": 68, "left": 255}, "words": "药代动力学资料表明,肝硬化病人氯沙坦的血浆浓度明显增加,故对有肝功能损害病史"}, {"probability": {"variance": 5e-05, "average": 0.99605, "min": 0.966779}, "location": {"width": 426, "top": 1172, "height": 52, "left": 210}, "words": "的病人应该考虑使用较低剂量(见用法和用量"}, {"probability": {"variance": 0.000103, "average": 0.989825, "min": 0.979686}, "location": {"width": 93, "top": 1169, "height": 56, "left": 1043}, "words": "药有"}, {"probability": {"variance": 0, "average": 0.999495, "min": 0.999037}, "location": {"width": 109, "top": 1233, "height": 28, "left": 213}, "words": "肾功能损害"}, {"probability": {"variance": 0.002345, "average": 0.98985, "min": 0.692938}, "location": {"width": 840, "top": 1234, "height": 70, "left": 260}, "words": "由于抑制了肾素一血管紧张素系统,已有关于敏感个体出现包括肾衰在内的肾功能的变化"}, {"probability": {"variance": 0.000245, "average": 0.996095, "min": 0.924473}, "location": {"width": 480, "top": 1293, "height": 55, "left": 214}, "words": "的报导;停止治疗后,这些肾功能的变化可以恢复"}, {"probability": {"variance": 2e-06, "average": 0.998851, "min": 0.994544}, "location": {"width": 842, "top": 1317, "height": 69, "left": 263}, "words": "对于肾功能依赖于肾素一血管紧张素一醛固酮系统活性的病人(如严重的充血性心力衰"}, {"probability": {"variance": 0.000223, "average": 0.994499, "min": 0.932606}, "location": {"width": 878, "top": 1360, "height": 70, "left": 218}, "words": "竭病人),应用血管紧张素转换酶抑制剂治疗可引起少尿和/或进行性氮质血症以及(罕有)"}, {"probability": {"variance": 0.000917, "average": 0.992489, "min": 0.84134}, "location": {"width": 552, "top": 1417, "height": 55, "left": 220}, "words": "急性肾功能衰竭和/或死亡。使用氯沙坦治疗也有类似报道"}, {"probability": {"variance": 0.082415, "average": 0.686653, "min": 0.399573}, "location": {"width": 138, "top": 1400, "height": 78, "left": 952}, "words": " KCD PHARM"}, {"probability": {"variance": 0, "average": 0.721627, "min": 0.721627}, "location": {"width": 20, "top": 1417, "height": 25, "left": 1095}, "words": "C"}, {"probability": {"variance": 0, "average": 0.999643, "min": 0.999023}, "location": {"width": 169, "top": 1474, "height": 40, "left": 1000}, "words": "杭州默沙东"}, {"probability": {"variance": 0.000129, "average": 0.994225, "min": 0.966954}, "location": {"width": 217, "top": 1518, "height": 36, "left": 953}, "words": "制药有限公司8"}], "language": 3}